Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Equity (2016 - 2025)

Northwest Biotherapeutics' Return on Equity history spans 15 years, with the latest figure at 0.26% for Q4 2025.

  • Quarterly results put Return on Equity at 0.26% for Q4 2025, down 3.0% from a year ago — trailing twelve months through Dec 2025 was 0.26% (down 3.0% YoY), and the annual figure for FY2025 was 0.78%, down 26.0%.
  • Return on Equity for Q4 2025 was 0.26% at Northwest Biotherapeutics, up from 0.23% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 1.12% in Q2 2023 to a low of 0.22% in Q3 2021.
  • The 5-year median for Return on Equity is 0.49% (2022), against an average of 0.56%.
  • The sharpest move saw Return on Equity surged 55bps in 2023, then tumbled -67bps in 2025.
  • Year by year, Return on Equity stood at 0.27% in 2021, then skyrocketed by 128bps to 0.62% in 2022, then soared by 45bps to 0.89% in 2023, then tumbled by -68bps to 0.29% in 2024, then decreased by -11bps to 0.26% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.26%, 0.23%, and 0.24% for Q4 2025, Q3 2025, and Q2 2025 respectively.